PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

BACKGROUND: Clinical trials of immune checkpoints modulators, including both programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors, have recently shown promising activity and tolerable toxicity in pre-treated NSCLC patients. However the predictive role of PD-L1 express...

Descripción completa

Detalles Bibliográficos
Autores principales: Passiglia, Francesco, Bronte, Giuseppe, Bazan, Viviana, Natoli, Clara, Rizzo, Sergio, Galvano, Antonio, Listì, Angela, Cicero, Giuseppe, Rolfo, Christian, Santini, Daniele, Russo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991415/
https://www.ncbi.nlm.nih.gov/pubmed/26918451
http://dx.doi.org/10.18632/oncotarget.7582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991415/
https://www.ncbi.nlm.nih.gov/pubmed/26918451
http://dx.doi.org/10.18632/oncotarget.7582

Ejemplares similares